Improved discrimination of benign and malignant lesions on FDG PET/CT, using comparative activity ratios to brain, basal ganglia, or cerebellum.
OBJECTIVE
This study demonstrates a simple background correction method, which improves the discrimination of benign from malignant lesions on FDG PET-CT imaging, using activity ratios compared with brain, basal ganglia, or cerebellum.


METHODS
Standardized uptake values (SUVs) and comparative activity ratios (CARs) were determined for FDG uptake in 92 lesions (39 benign and 53 malignant) in 49 patients. Reference tissues included cerebral cortex, basal ganglia, cerebellum, lung, liver, and aortic blood pool. Discriminant power for each CAR was evaluated as malignant-to-benign ratio of mean uptake and ratio of intermediate-likelihood lesions to total number of lesions.


RESULTS
Uncorrected SUV varied widely for malignant and benign lesions, with considerable overlap. Ratio of mean uptake for malignant lesions versus benign lesions was lowest for uncorrected SUVAVG and SUVAVG/liver (1.92), and highest for SUVMAX/cerebral cortex (3.52). Lesions could be separated into very high (> 90%), very low (< 10%), and intermediate (> or = 10% and < or = 90%) likelihood of malignancy. The ratio of intermediate-likelihood lesions to the total number of lesions was greatest for SUVAVG (0.42) and lowest for SUVMAX/basal ganglia (0.22).


CONCLUSIONS
Ability to discriminate malignant from benign lesions was enhanced by using CARs derived from cerebral cortex, basal ganglia, or cerebellum. Using a 3-tiered diagnostic schema, most lesions could be assigned to categories of very high or very low likelihood of malignancy, with a significant reduction in indeterminant lesions, compared with uncorrected SUV.
Britz-Cunningham
Scott H
SH
Division of Nuclear Medicine, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA. sbritzcunningham@partners.org
Millstine
John W
JW
Gerbaudo
Victor H
VH
D001921:Brain / Q000000981:diagnostic imaging; D001932:Brain Neoplasms / Q000175:diagnosis*; D003937:Diagnosis, Differential; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007089:Image Enhancement / Q000379:methods*; D007090:Image Interpretation, Computer-Assisted / Q000379:methods*; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed / Q000379:methods*
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18